{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-031039","form_type":"8-K","ticker":"MASS","cik":"0001555279","company_name":"908 Devices Inc.","filed_at":"2022-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.970590+00:00","generated_at":"2026-06-27T01:09:21.660338+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"908 Devices Q4 rev $15.8M (+177% YoY); net loss $3.5M; FY22 guide $52-55M","bullets":["Full-year 2021 revenue $42.2M (+57% YoY); net loss $22.2M ($0.79 loss per share).","Q4 gross margin improved to 58% from 49%; installed base expanded to 1,935 devices.","Cash $224M at year-end; debt outstanding $15M.","FY 2022 revenue outlook $52M-$55M, representing 23%-30% growth over FY 2021.","Commercial traction with all top 20 biopharma; Tony Hunt (Repligen CEO) added to board."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-031039","json":"https://secwatch.observer/filing/0001104659-22-031039.json","markdown":"https://secwatch.observer/filing/0001104659-22-031039.md","text":"https://secwatch.observer/filing/0001104659-22-031039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1555279/000110465922031039/0001104659-22-031039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1555279/000110465922031039/tm228482d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T01:09:21.660338+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}